NCT04504669 - First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions

Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast NeoplasmsSquamous Cell Cancer of Head and NeckSmall Cell Lung CancerGastroesophageal CancerMelanomaCervical CancerAdvanced Solid Tumours

Interventions

DRUG

AZD8701

FOXP3 antisense oligonucleotide

BIOLOGICAL

Durvalumab

anti PDL-1 monoclonal antibody

Trial Locations (13)

21287

Research Site, Baltimore

28027

Research Site, Madrid

28041

Research Site, Madrid

28078

Research Site, Huntersville

35000

Research Site, Rennes

37067

Research Site, Franklin

53792

Research Site, Madison

63110

Research Site, St Louis

77030

Research Site, Houston

94805

Research Site, Villejuif

M5G 2M9

Research Site, Toronto

08035

Research Site, Barcelona

08907

Research Site, L'Hospitalet de Llobregat